Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ONCY

Oncolytics Biotech, Inc.

May 15 • 09:48AM ET

1.20

Dollar change +0.02
Percentage change 1.69	%

Healthcare • Biotechnology • Canada • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.30	Insider Own	6.33%	Shs Outstand	74.42M	Perf Week	1.69%
Market Cap	90.50M	Forward P/E	-	EPS next Y	-0.27	Insider Trans	0.00%	Shs Float	70.65M	Perf Month	11.11%
Income	-20.95M	PEG	-	EPS next Q	-0.08	Inst Own	6.75%	Short Float	1.22%	Perf Quarter	4.35%
Sales	0.00M	P/S	-	EPS this Y	1.08%	Inst Trans	29.70%	Short Ratio	2.75	Perf Half Y	-14.29%
Book/sh	0.23	P/B	5.33	EPS next Y	10.56%	ROA	-80.92%	Short Interest	0.86M	Perf Year	-26.83%
Cash/sh	0.29	P/C	4.14	EPS next 5Y	-	ROE	-116.39%	52W Range	0.88 - 3.39	Perf YTD	-11.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.01%	ROI	-118.55%	52W High	-64.65%	Beta	1.90
Dividend TTM	-	Quick Ratio	8.14	Sales past 5Y	0.00%	Gross Margin	-	52W Low	35.90%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	8.14	EPS Y/Y TTM	3.23%	Oper. Margin	0.00%	RSI (14)	60.95	Volatility	6.52% 4.96%
Employees	27	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	4.93
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	11.01%	Payout	-	Rel Volume	2.12	Prev Close	1.18
Sales Surprise	-	EPS Surprise	20.89%	Sales Q/Q	-	Earnings	May 09 AMC	Avg Volume	312.62K	Price	1.20
SMA20	7.00%	SMA50	10.28%	SMA200	-19.93%	Trades		Volume	62,113	Change	1.69%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-22	Initiated	Maxim Group	Buy	$3
Feb-17-21	Initiated	H.C. Wainwright	Buy	$15

Today 08:03AM	Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial (MT Newswires)
07:00AM	Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial (PR Newswire)
May-10-24 04:35PM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript (Insider Monkey) -5.65%
May-09-24 08:59PM	ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024 (InvestorPlace) +5.08%
04:21PM	Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million (MT Newswires)
04:01PM	Loading…
04:01PM	Oncolytics Biotech Reports First Quarter 2024 Financial Results and Operational Highlights (PR Newswire)
12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire)
10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire)
08:08AM	Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer (MT Newswires)
07:00AM	Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer (PR Newswire)
May-08-24 07:00AM	Oncolytics Biotech to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference (PR Newswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
07:00AM	Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Apr-25-24 07:00AM	Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting (PR Newswire)
09:15AM	Loading…
Apr-11-24 09:15AM	Biotech Innovations Paving the Way in Breast Cancer Fight (PR Newswire)
07:00AM	Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA (PR Newswire)
Apr-02-24 07:00AM	Oncolytics Biotech to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference (PR Newswire)
Mar-14-24 08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-10-24 08:36AM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:55PM	ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (PR Newswire)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 08:30AM	Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments (GlobeNewswire) +11.96%
07:00AM	Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN (PR Newswire)
Mar-04-24 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire) -17.86%
Feb-28-24 07:00AM	Oncolytics Biotech Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference (PR Newswire)
Feb-15-24 08:00AM	Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments (Newsfile)
Feb-14-24 08:30AM	Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies (GlobeNewswire) +9.52%
07:00AM	Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort (PR Newswire)
08:55AM	Loading…
Feb-07-24 08:55AM	Pancreatic Cancer Treatments Poised for Major Advances in 2024 (PR Newswire) -14.94%
Jan-09-24 10:25AM	Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 (GlobeNewswire) -8.82%
07:00AM	Oncolytics Biotech Appoints Patricia S. Andrews to its Board of Directors (PR Newswire)
Jan-04-24 07:00AM	Oncolytics Biotech Recaps 2023 Accomplishments, Provides Outlook for 2024 (PR Newswire)
Dec-07-23 07:00AM	Oncolytics Biotech and SOLTI Present Positive Translational Data at SABCS (PR Newswire)
Nov-29-23 10:45AM	Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment (PR Newswire)
Nov-09-23 08:45AM	Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance (PR Newswire) -15.92%
07:00AM	Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy (PR Newswire)
06:30AM	Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep (PR Newswire)
Nov-05-23 02:29PM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 12:03PM	Oncolytics Biotech and SOLTI Present Further Positive Pelareorep Translational Data at SITC (PR Newswire)
07:00AM	Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlights (PR Newswire)
Oct-23-23 09:50AM	Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise (PR Newswire) +9.03%
08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire)
07:05AM	Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO (PR Newswire)
07:00AM	Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study (PR Newswire)
Oct-20-23 10:31AM	Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research (PR Newswire)
07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Oct-16-23 07:00AM	Oncolytics Biotech To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023 (PR Newswire)
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-26-23 08:00AM	THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS (PR Newswire)
Sep-19-23 07:00AM	Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference (PR Newswire)
Sep-07-23 09:22AM	Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering (PR Newswire) -5.83%
Sep-06-23 07:00AM	Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-21-23 07:00AM	3 Under-$20 Stocks to Buy for Explosive Returns (InvestorPlace)
Aug-17-23 09:35AM	After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY) (Zacks)
Aug-14-23 07:00AM	Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights (PR Newswire)
Aug-08-23 08:50AM	Oncolytics Biotech® Successfully Raises US$15 Million to Advance Breast and Pancreatic Cancer Clinical Programs (PR Newswire)
Aug-04-23 07:05AM	Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 43rd Annual Growth Conference (PR Newswire)
07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Jul-31-23 06:55AM	Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units (PR Newswire) -10.32%
Jun-22-23 07:00AM	Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial (PR Newswire) +16.67%
Jun-05-23 07:00AM	Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate (PR Newswire)
May-26-23 11:30AM	Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting (PR Newswire) -18.98%
May-25-23 05:41PM	Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives 50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract (PR Newswire)
May-24-23 10:26AM	CANADA STOCKS-TSX tumbles as bank earnings, US debt deal uncertainty weigh (Reuters) +20.11%
May-10-23 07:00AM	Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
May-07-23 01:18PM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-05-23 07:00AM	Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights (PR Newswire) +10.34%
Apr-26-23 10:44AM	Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting (PR Newswire) +12.39%
Apr-12-23 07:23AM	Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference (PR Newswire)
07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire)
06:45AM	Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders (PR Newswire)
Mar-28-23 07:00AM	Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium (PR Newswire)
Mar-27-23 11:57AM	Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Mar-06-23 09:48AM	Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 07:00AM	Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights (PR Newswire) -5.36%
Feb-21-23 07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire)
Dec-16-22 09:40AM	Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year? (Zacks) +6.56%
Dec-08-22 08:45AM	Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium (PR Newswire)
Dec-05-22 12:00PM	What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-02-22 10:59AM	Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag (Zacks) -12.74%
09:15AM	Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? (Zacks)
Dec-01-22 07:32AM	Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer (PR Newswire) +20.45%
Nov-29-22 09:40AM	Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year? (Zacks) +6.49%
Nov-21-22 09:01AM	Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium (PR Newswire)
Nov-18-22 09:55AM	Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Nov-10-22 09:01AM	Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort (PR Newswire) +10.11%
Nov-07-22 08:03AM	Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights (PR Newswire) +19.05%
08:01AM	Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting (PR Newswire)
Oct-27-22 07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights (PR Newswire)
Oct-18-22 10:46AM	We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate (Simply Wall St.)
Sep-07-22 07:00AM	Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors (PR Newswire)
Aug-11-22 07:00AM	Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights (PR Newswire)
Jul-27-22 07:00AM	Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights (PR Newswire) -6.25%
Jul-11-22 06:19AM	Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech (Zacks)
Jun-28-22 07:00AM	Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET (PR Newswire)
Jun-17-22 07:00AM	Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors (PR Newswire) +10.13%
Jun-01-22 12:21PM	IIROC Trading Halt - ONC.WT (PR Newswire)

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ONCY

Oncolytics Biotech, Inc.

Upgrade your FINVIZ experience